Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03846505
Other study ID # Pro00082233
Secondary ID 1R01AA027212
Status Completed
Phase Phase 2
First received
Last updated
Start date May 16, 2019
Est. completion date January 31, 2024

Study information

Verified date June 2024
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Alcohol Behavioral Couples Therapy (ABCT) is a manualized 12-session, weekly psychosocial intervention that simultaneously reduces alcohol use disorder (AUD) severity and improves relationship functioning. However, there remains room to improve ABCT outcomes. A growing literature suggests that intranasal oxytocin is a medication that holds promise to achieve that goal. Oxytocin has demonstrated the ability to increase prosocial behavior (e.g., trust, safety, social cognition) and restore sensitivity to natural rewards such as interpersonal relationships that are commonly eroded in the context of addiction. Oxytocin has also demonstrated the ability to reduce substance use behaviors (e.g., craving, self-administration, tolerance, withdrawal), and improves the neurobiological foundations of AUD. The primary objective of this Stage II study is to test the efficacy of oxytocin versus placebo in improving (1) AUD symptom severity, (2) relationship functioning, and (3) corticolimbic connectivity among couples receiving ABCT therapy.


Recruitment information / eligibility

Status Completed
Enrollment 194
Est. completion date January 31, 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Male or female; any race or ethnicity; aged 18-75 years. 2. Able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of the assessment instruments (> 26 on the Mini-Mental State Exam). 3. Married, cohabiting for = 6 months, or in a committed relationship of at least 1-year duration. 4. =1 hazardous drinking episode in past 60 days by IP. 5. Identified Patients (IPs) must meet DSM-5 diagnostic criteria for current (i.e., past 6 months) alcohol use disorder. Couples in which both partners meet diagnostic criteria for current AUD are eligible for participation. 6. Concurrent substance use disorders (e.g., marijuana) are acceptable provided that alcohol is the IP's primary substance of choice. 7. Participants taking psychotropic medications will be required to be maintained on a stable dose for at least four weeks before study initiation. This is because initiation or change of psychotropic medications during the course of the trial may interfere with interpretation of results. Exclusion Criteria: 1. Meeting DSM-5 criteria for a history of or current psychotic or bipolar affective disorders, or with current suicidal or homicidal ideation and intent. Those individuals will be referred clinically for treatment. 2. Participants who present a serious suicide risk or are likely to require hospitalization during the study. 3. History of seizures and/or seizure disorder 4. Severe unilateral intimate partner violence in the past 6 months as defined by the CTS-2. 5. Pregnancy or breastfeeding 6. Acute alcohol withdrawal as indicated by CIWA-Ar scores >8. They may be re-assessed once they are no longer in withdrawal. Those individuals will be referred for medically supervised detoxification. 7. Any unstable or serious medical condition affecting the potential participants' ability to participate in the study 8. Individuals with claustrophobia; tattoos above the shoulders; permanent eyeliner or permanent artificial eyebrows; cardiac pacemaker; metal fragments in eye, skin, or body, including shrapnel; heart valve replacement; brain clips; venous umbrella; current or former sheet-metal worker or welder; lifetime history of aneurysm surgery; lifetime history of seizures and/or epilepsy; intracranial bypass, renal, or aortic clips; prosthetic devices such as middle ear, eye, joint, or penile implants; joint replacements; non-removable hearing aid, neurostimulator, or insulin pump; shunts/stents; metal mesh/coil implants; metal plate/pin/screws/wires; or any other MRI contraindications as determined by the MRI technician at the time of scanning will not be eligible to participate in the neuroimaging component of the study, however individuals who meet inclusion/exclusion criteria for the medication component of the study but not the MRI portion will still be eligible to reenroll in and complete the medication/treatment phase.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oxytocin
A 40-IU dose of oxytocin will be self-administered 30 minutes prior to the start of each weekly ABCT session.
Other:
Placebo
A placebo will be self-administered 30 minutes prior to the start of each weekly ABCT session.

Locations

Country Name City State
United States Medical University of South Carolina Charleston South Carolina

Sponsors (2)

Lead Sponsor Collaborator
Medical University of South Carolina National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent Days Abstinent Time Line Follow Back (TLFB), a clinician assessed measure, will be used to report percent days abstinent (days with no alcohol consumption) and percent days heavy drinking (5 or more days of binge drinking per month). Baseline to 6 month follow up
Primary Total Score of Relationship Functioning Dyadic Adjustment Scale, a self-report survey, will be used to assess relationship functioning. Scores can range from 0 to 151, with a higher score indicating greater relationship functioning. Baseline to 6 month follow up
Primary Percent Days Heavy Drinking Time Line Follow Back (TLFB), a clinician assessed measure, will be used to report percent days heavy drinking (5 or more days of binge drinking per month). Baseline to 6 month follow up
See also
  Status Clinical Trial Phase
Recruiting NCT04788004 - Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
Recruiting NCT05684094 - Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function N/A
Completed NCT03406039 - Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems N/A
Completed NCT03573167 - Mobile Phone-Based Motivational Interviewing in Kenya N/A
Completed NCT04817410 - ED Initiated Oral Naltrexone for AUD Phase 1
Active, not recruiting NCT04267692 - Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders N/A
Completed NCT03872128 - The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders Phase 1
Completed NCT02989662 - INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers Phase 1/Phase 2
Recruiting NCT06030154 - Amplification of Positivity for Alcohol Use N/A
Active, not recruiting NCT05419128 - Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04203966 - Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
Recruiting NCT05861843 - Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Enrolling by invitation NCT04128761 - Decreasing the Temporal Window in Individuals With Alcohol Use Disorder N/A
Not yet recruiting NCT06444243 - Psilocybin-assisted Therapy for Alcohol Use Disorder Phase 2
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Not yet recruiting NCT06337721 - Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults N/A
Enrolling by invitation NCT02544581 - Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare N/A